

Artit Ungkanont

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11426780/publications.pdf>

Version: 2024-02-01

12
papers

263
citations

1163117

8
h-index

1372567

10
g-index

12
all docs

12
docs citations

12
times ranked

454
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of Transplantation with Related- and Unrelated-Donor Stem Cells in Children with Severe Thalassemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 683-687.	2.0	55
2	Outcomes of Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation by Using a Standard Myeloablative versus a Novel Reduced-Toxicity Conditioning Regimen According to a New Risk Stratification. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2066-2071.	2.0	43
3	Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. <i>Leukemia Research</i> , 2006, 30, 1493-1498.	0.8	36
4	Pretransplant Immunosuppression followed by Reduced-Toxicity Conditioning and Stem Cell Transplantation in High-Risk Thalassemia: A Safe Approach to Disease Control. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1259-1262.	2.0	35
5	Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. <i>American Journal of Hematology</i> , 2007, 82, 1095-1098.	4.1	30
6	Treatment outcome and prognostic factors in PCNSL. <i>Diagnostic Pathology</i> , 2019, 14, 56.	2.0	24
7	Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2019, 8, 3.	5.0	17
8	The use of hematocrit level for predicting the efficiency of peripheral blood CD ³⁴ ⁺ cell collection after G-CSF Mobilization in Healthy Donors. <i>Journal of Clinical Apheresis</i> , 2015, 30, 329-334.	1.3	16
9	Host Origin of Marrow Mesenchymal Stem Cells Following Allogeneic Cord-Blood Stem-Cell Transplantation. <i>International Journal of Hematology</i> , 2001, 74, 235-236.	1.6	6
10	TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021063.	1.3	1
11	Outcomes of Transplantation with Matched-Related Donor (MRD) and Alternative Donor (AD) Stem Cells in Children with Severe Thalassemia.. <i>Blood</i> , 2004, 104, 2160-2160.	1.4	0
12	Reduced Intensity Hematopoietic Stem Cell Transplantation for Treatment of Class 3 Lucarelli Severe Thalassemia Patients.. <i>Blood</i> , 2006, 108, 5364-5364.	1.4	0